NIBN at a Glance
The National Institute for Biotechnology in the Negev Ltd. (NIBN), a unique research institute located within Ben-Gurion University of the Negev (BGU), is the first self-organized, independent research entity established under the auspices of a university in Israel.
The NIBN was established as a company in November 2009 through a trilateral agreement between the Israeli Government, Mr. Edgar de Picciotto, and Ben-Gurion University.
The mission of the NIBN is to conduct multi-disciplinary applied research guided by a clear biotechnology vision, to bridge the gap between basic and applied innovative research, and facilitate the commercialization of novel ideas and technologies developed by NIBN researchers.
Research at the NIBN is focused in several key areas: cancer, infectious diseases, autoimmune and metabolic diseases, human genetic disorders, neurodegenerative diseases, and applied biotechnology, including AgBio. The decision to focus on these topics combines existing strengths and resources unique to the NIBN and BGU.
The NIBN aims to encourage its members to cross academic barriers, which, by longstanding tradition, have isolated scientific disciplines, and instead engage in creative and groundbreaking biotechnological research with commercialization potential. Hosted within Ben-Gurion University, the NIBN represents a framework that is different from existing academic models, yet incorporates the creative university setting and dedication to research excellence, and creates an environment conducive to advancing pioneering ideas.
The NIBN strives to achieve its mission by providing NIBN researchers with state-of-the-art laboratories, research grants, infrastructure support units, intellectual property, and project management and business development leadership delivered by NIBN’s professional management team.
Our vision is ultimately to contribute to the establishment of a successful biotechnology industrial hub in Israel, and particularly in the Negev.